Industrial Rhamnolipid Market Intelligence: Size, Share and Growth Outlook Through 2035

Market Overview

Size, scope, and commercial definition

• Brevintel analysis values the industrial rhamnolipid market at USD 467.8 million in 2025 ($468M), rising to USD 500.1 million in 2026 and USD 950.5 million by 2035 ($951M) at an 8.4% CAGR over 2026–2035.
• Headline cards therefore lock $468M, $951M, and 8.4%, matching the 2025–2035 narrative path and the 2026–2035 forecast window.
• Historic expansion ran at 6.7% during 2022–2024, when production economics and qualification cycles still constrained conversion from evaluation to repeat orders.
• Rhamnolipids are fermentation-derived glycolipid biosurfactants whose rhamnose head group and fatty-acid chains control surface and interfacial tension in aqueous systems.
• The commercial market covers liquid and powder products in technical, high-purity, and ultra-high-purity grades sold into industrial-scale uses; laboratory lots below 1 kg, sophorolipids, synthetic surfactants, and captive output are excluded.
• Evonik Industries AG led with over 12% share in 2025, while Evonik, Stepan Company, AGAE Technologies LLC, Jeneil Biotech Inc, and GlycoSurf collectively held 43%.
• In May 2024 Evonik inaugurated an industrial-scale rhamnolipid plant in Slovenská Ľupča, Slovakia, shifting the commercial question from availability toward application conversion.
• The estimate follows demand-side revenue recognized by commercial producers and distributors and reconciles type, form, grade, end-use, and regional builds to the global total.
• The value chain starts with sugars and vegetable oils, then fermentation, extraction, purification, formulation, distribution, and end-user deployment, with feedstock and purification setting the premium versus petrochemical surfactants.

From specialty supply to formulation qualification

• Brevintel analysis sees demand moving from a supply-constrained specialty market toward a qualification-constrained formulation market through 2030.
• Industrial-scale output removes one barrier, but users still must validate foam behavior, interfacial performance, impurity tolerance, and dosage inside their own systems.
• The stronger commercial shift occurs where environmental compliance and formulation performance outweigh the delivered-cost premium.
• Oilfield chemistry and technical cleaning provide volume, while high-purity personal care and pharmaceutical uses create the strongest incentive to improve downstream processing.
• By 2035, suppliers that pair fermentation scale with application support are positioned to capture more value than suppliers competing on biosurfactant identity alone.

Market Dynamics

Demand drivers

• Enhanced oil recovery is the largest near-term volume engine because oil and gas represented 40.2% of 2025 revenue.
• Rhamnolipids reduce interfacial tension between oil and water, supporting mobilization in mature reservoirs and selected drilling-fluid and well-treatment formulations.
• Industry data from the International Energy Agency identifies enhanced oil recovery as a pathway for extracting additional resources from existing fields.
• Biodegradability adds commercial relevance where discharge restrictions or environmental permitting raise the cost of conventional surfactant selection.
• Personal care expands the addressable market through formulation substitution rather than bulk volume alone, using rhamnolipids as mild surfactants and emulsification aids in water-based systems.
• Evonik’s Slovakia output is directed to cleaning, beauty, and personal care, giving formulators a scaled commercial reference for this use case.
• EU chemicals policy under REACH and the European Green Deal, together with the U.S. EPA Safer Choice program, strengthen procurement criteria for biodegradability and lower-hazard positioning.
• These frameworks do not automatically prescribe rhamnolipids, but they make sustainability documentation part of supplier qualification rather than a marketing extra.

Restraints and commercial constraints

• Fermentation, extraction, purification, and formulation keep delivered cost above conventional petrochemical surfactants, narrowing adoption where performance does not offset price.
• Scale can improve fixed-asset utilization, but it cannot make every commodity surfactant application economically accessible within the forecast period through 2035.
• Sugar, vegetable-oil, glycerol, and other carbohydrate inputs link rhamnolipid economics to agricultural commodity cycles and competing food, fuel, and biochemical demand.
• Production regions with feedstock access and established fermentation infrastructure can respond more effectively to input volatility than import-dependent markets.
• That supply logic favors China, Europe, and North America as production bases while raising the commercial risk of rapid capacity replication elsewhere.
• Oilfield users need evidence that a biosurfactant works with their water chemistry, equipment, and permitting, which lengthens conversion even after capacity exists.
• Pharmaceutical and healthcare applications face stricter purity and documentation requirements because rhamnolipids may function in biocompatible delivery architectures.
• Brevintel analysis treats the principal constraint as the gap between technical feasibility and repeatable commercial use, not a lack of demand awareness.

Segmentation Analysis

Type

• Mono-rhamnolipids generated USD 282.3 million in 2025 and accounted for 60.4% of market value.
• Their 7.8% CAGR reflects workhorse use in oilfield chemistry, industrial cleaning, and environmental applications, where surface activity, solubility, and cost-to-performance balance matter.
• One rhamnose unit supports broad use in technical-grade liquid and powder formulations, tying mono-rhamnolipids to the liquid, technical-grade, and oil-and-gas pools that dominate current demand.
• Di-rhamnolipids generated USD 185.5 million in 2025 and will expand at a faster 9.1% CAGR.
• Two rhamnose units can support stronger emulsification stability and durability in more demanding chemical environments.
• That profile is more relevant to high-specification cosmetics, pharmaceutical delivery, and specialized oilfield formulations that can support higher purification costs.
• The strategic split is therefore mono-rhamnolipids for scalable industrial deployment and di-rhamnolipids for performance-sensitive uses.

Form

• Liquid rhamnolipids accounted for USD 330.3 million, or 70.6% of 2025 revenue, and will grow at an 8.1% CAGR.
• Ready-to-use products fit smaller-volume users that prioritize handling convenience, while concentrates reduce freight and storage for high-throughput customers.
• Aqueous suspensions address specialized rheology and blending needs in continuous oilfield dosing, industrial cleaning, and water-based personal care manufacture.
• The ability to meter a liquid directly into an existing system gives the format commercial value beyond chemistry alone.
• Powder products represented USD 137.5 million in 2025 and will grow at an 8.9% CAGR.
• Spray-dried products are the principal broad-use powder format, bulk industrial powders serve transport and storage, and freeze-dried products align with high-purity specialty applications.
• Powder reduces shipped water and can improve shelf-life management for agricultural bio-adjuvants and dry-blend formulations.
• The faster powder outlook reflects logistics and dosing advantages rather than displacement of liquid products, so suppliers need both forms.

Grade

• Technical grade 85–90% rhamnolipids held 67.3% share and generated USD 314.9 million in 2025.
• The grade will grow at an 8.1% CAGR because it serves high-volume, price-sensitive applications including EOR, industrial and institutional cleaning, agriculture, and environmental remediation.
• Its commercial appeal lies in accepting the composition typical of fermentation-derived material while delivering fit-for-purpose surface-active performance.
• This grade benefits most directly when large-scale fermentation reduces unit cost.
• High purity grade 90–95% generated USD 78.0 million in 2025 and will expand at 9.3%, the fastest grade-level CAGR.
• Cosmetics and specialized industrial formulations require tighter impurity and consistency control, so the segment values downstream processing as much as fermentation output.
• Ultra-high purity material above 95% generated USD 74.9 million and will grow at 8.4%, supported by pharmaceutical and advanced biotechnology applications.
• Purification capability therefore determines access to the smallest but most specification-intensive demand pools, so market value cannot be read from tonnage alone.

End-use

• Oil and gas generated USD 188.1 million in 2025 and accounted for 40.2% of market value, growing at an 8.0% CAGR through EOR, drilling fluids, and well-treatment chemistry.
• The segment anchors demand for technical-grade liquid products, especially in the U.S., China, Saudi Arabia, the UAE, and Brazil, though field qualification keeps conversion cycles long.
• Agriculture generated USD 95.7 million in 2025 and will grow at 9.1%, with rhamnolipids used as bio-adjuvants, soil conditioners, biopesticide synergists, and plant-defense elicitors.
• India, Brazil, and Mexico provide the core agricultural growth geographies, and dry mixing favors powder products that connect the fastest end-use to the faster-growing form.
• Pharmaceuticals and healthcare generated USD 76.0 million in 2025 and will grow at 8.8%, reflecting amphiphilic use in emulsification, encapsulation, and nanoparticle-oriented delivery research.
• Cosmetics and personal care generated USD 75.8 million and will grow at 8.1%, supported by mild-surfactant and clean-formulation positioning.
• The others category, including textiles, household and industrial cleaners, and bioremediation, generated USD 32.3 million and will grow at 7.8%.
• Brevintel analysis expects mono-rhamnolipids, liquids, technical grades, and oil and gas to remain the revenue foundation, while di-rhamnolipids, powders, high-purity grades, and agriculture outpace the aggregate market.

Regional Outlook

Asia Pacific

• Asia Pacific is the largest market, generating USD 162.1 million in 2025 and growing at an 8.9% CAGR through 2035.
• China combines fermentation supply capability with demand from EOR and industrial cleaning, generating USD 61.6 million in 2025.
• India generated USD 16.2 million and will grow at 9.8%, supported by agricultural bio-adjuvants and pharmaceutical manufacturing.
• Japan, South Korea, and Australia add demand in cosmetics, advanced cleaning, and pharmaceutical applications.
• The regional advantage comes from feedstock access, fermentation infrastructure, and broad industrial demand; the constraint is maintaining consistent quality as producers expand export channels.

North America and Europe

• North America generated USD 132.9 million in 2025 and held 28.4% share.
• The U.S. accounted for USD 109.6 million, supported by EOR, industrial and institutional cleaning, and personal care formulation under the EPA Safer Choice framework.
• Canada complements the U.S. base through oil-sands-related recovery applications and food-processing and cleaning demand.
• The region will grow at 7.6%, a slower rate that reflects a larger existing base and mature customer qualification practices rather than weak demand.
• Europe generated USD 110.9 million in 2025 and will grow at 7.8%.
• Germany generated USD 31.1 million, benefiting from specialty chemical formulators and proximity to Evonik’s Slovakia supply base.
• The UK, France, Spain, and Italy provide demand across personal care, agriculture, and industrial cleaning, reinforced by REACH and the European Green Deal.
• Europe therefore has a compliance-led demand case and a localized-scale-supply advantage, although price and validation still govern substitution.

Latin America and Middle East & Africa

• Latin America generated USD 36.3 million in 2025, held 7.8% share, and is the fastest-growing region at 9.5%.
• Brazil generated USD 18.1 million, driven by EOR activity, agriculture, and environmental applications, while Mexico and Argentina extend the agricultural and biotechnology demand base.
• Regional growth rests on end-use expansion, but suppliers must still provide distribution coverage and local technical support.
• The Middle East and Africa generated USD 25.7 million and held 5.5% share in 2025.
• The region will grow at 9.3%, led by EOR-related demand in Saudi Arabia and the UAE, alongside environmental remediation and specialty chemical distribution in South Africa.
• Oilfield applications provide a clear use case, but feedstock dependence and a thinner local fermentation base keep the near-term market more dependent on imported material and distributors.
• Brevintel analysis sees regional leadership through 2035 in markets where suppliers combine local technical service with dependable material availability.

Competitive Landscape

Structure, capacity, and recent developments

• Evonik Industries AG leads with an estimated 12% share, while the top five suppliers collectively hold 43%, leaving a large residual market for regional specialists.
• The HHI calculation using the individual top-five estimates and the residual category yields approximately 2,256, indicating moderate concentration and remaining directional because private-company shares are estimates.
• Evonik’s position rests on the Slovakia plant and the REWOFERM RL range for cleaning, beauty, and personal care, converting a technology-scale argument into a supply-scale argument.
• Stepan Company competes through an established surfactant platform and the STEPANGREEN rhamnolipid range into existing personal care and cleaning accounts.
• In March 2025, Chemical & Engineering News reported that AGAE Technologies’ Asian biosurfactant facility reached full-scale production, with capacity above 1,000 metric tons per year.
• Jeneil Biotech Inc holds a long-established fermentation position through its JBR portfolio, including mono- and di-rhamnolipid products.
• In March 2024, Chemical & Engineering News reported that Holiferm Ltd was no longer making rhamnolipids, so its competitive-scope listing should not be read as verified active production.
• By 2028, price pressure in technical grades is expected to intensify, while qualification and documentation preserve differentiation in high-purity applications.
• Starchem Enterprises Limited supplies 80% and 95% glycolipid grades for industrial end uses, illustrating how purity bands sit beside the 85–90% and 90–95% commercial grade structure.

Integrated producers

• Evonik Industries AG
• Stepan Company

Specialty suppliers

• AGAE Technologies LLC
• Jeneil Biotech Inc
• GlycoSurf
• Holiferm Ltd
• Seebio Biotech (Shanghai) Co., Ltd.
• Starchem Enterprises Limited

Regional players

• Zhejiang Silver Elephant Bio-engineering Co. Ltd
• Shaanxi Deguan Biotechnology Co. Ltd
• Xi'an Rege Biotechnology Co., Ltd.